myeloma, 5 breast and ovarian cancer. [6] [7] [8] Also, mobilization severe combined immune-deficient (SCID) mice engrafted with human leukaemia. Three leukaemia cell of PBSCs has been shown to be accompanied by recruitment of tumour cells into the PB of patients with myelines were investigated: the HL60 myeloblastic cell line, a chronic myeloid leukaemia (CML) xenograft cell line loma, 9,10 breast cancer or lung cancer, especially where disease has infiltrated the BM. 11 Administration of granulocyte and an acute myeloid leukaemia (AML) xenograft line. Engraftment was detected using immunofluorescent colony-stimulating factor (G-CSF) is frequently used to stimulate PBSC mobilization, yet little is known about the staining of class I human leukocyte antigens and flow cytometry. All the tumours grew as disseminated effects of this haemopoietic cytokine on the migration of leukaemia cells from the BM into the circulation.
disease with engraftment of bone marrow preceding involvement of peripheral blood (PB). After treatment
Human leukaemias proliferate and disseminate when implanted into severe combined immune-deficient (SCID) with G-CSF (250 g/kg/day) for 5 days, mobilization of haemopoietic progenitor cells (HPCs) was observed in mice. [12] [13] [14] [15] Xenografted cells can be passaged into fresh recipients with the karyotype and immunophenotype of the non-engrafted SCID mice (40-fold) and in mice engrafted with human leukaemia (20-fold). G-CSF malignant clone remaining essentially unchanged. 15, 16 The pattern of growth is similar to that seen in patients, with stimulated increases in PB HPCs and total numbers of host nucleated cells in leukaemia-bearing mice but did infiltration of many tissues including BM, spleen and PB.
We have investigated the mobilization of haemopoietic not induce rises in numbers of circulating HL60 colonyforming cells. Similarly, in mice engrafted with human cells into the PB of SCID mice following treatment with recombinant human G-CSF, a cytokine which crosses the CML or AML, G-CSF did not increase the number of malignant cells in the PB. These results provided evispecies barrier. We have also studied G-CSF-induced mobilization of normal and malignant cells in mice engrafted dence that the migration of normal and malignant haemopoietic cells into the PB are controlled by with human leukaemia cell populations. different mechanisms, and that contamination of PBSC harvests with leukaemic cells in SCID-human chimaeric mice is not enhanced by G-CSF-stimulated Materials and methods mobilization. Keywords: G-CSF; mobilization; xenograft; SCID mice
Human leukaemia xenografts
Male and female C.B.-17 SCID mice aged 3-6 months (originally supplied from Harlan UK Ltd, Bicester, UK and A concern regarding autotransplantation of bone marrow subsequently bred at this Institute) were housed in posi-(BM) or peripheral blood stem cells (PBSCs) is the risk of tively individually ventilated cages and supplied sterilized reintroducing tumour cells back into the patient. Using genfood and water ad libitum. Before implantation of human etic marking techniques it has been shown that following leukaemias, 2 Gy total body irradiation was delivered from autologous bone marrow transplantation (BMT) of patients a
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Cobalt source at a dose rate of approximately 0.5 Gy per in remission, leukaemia cells derived from the BM harvest min. All other procedures were performed within a class II were detected within the resurgent blast cell population microbiological safety cabinet under filtered lamina air during relapse. 1 In addition to producing more rapid flow. Cells were implanted intravenously in 0. 20 Twenty microlitres of PB were cells were scored using an inverted microscope (× 40 sampled from the tail and added to 30 l phosphate-buffmagnification). Twenty-four hours after the initial blood ered saline (PBS) containing 0.1% BSA and 50 units per ml sampling, treatment with G-CSF was started in three mice preservative-free heparin (PFH; Leo Laboratories, Princes and continued for 5 days. Three control mice were treated Risborough, UK). Samples were placed on ice and 2.5 l with PBS vehicle (PBS containing 0.1% BSA) alone. W632 antibody was added for 30 min. Red blood cells were Further PB samples were taken 24 h later and on the 4 folthen removed by the addition of 1 ml lysis solution (0.15 M lowing days immediately before treatments were given. ammonium chloride, 10 mM potassium bicarbonate, 0.1 mM Measurements of absolute neutrophil count (ANC) and prodisodium EDTA) for 10 min at room temperature. Samples genitor cell assays were performed on each sample. Numwere centrifuged at 350 g for 4 min, the supernatant bers of progenitor cells in the BM of untreated SCID mice removed and the cells washed using PBS buffer reagent were also measured using the agar culture method (PBR; Coulter Electronics, Luton, UK). Samples were described above. Suspensions of BM cells were obtained resuspended in 0.4 ml PBR and analysed using a Cytoron from six donors by flushing the contents of individual Absolute flow cytometer (Ortho Diagnostic Systems, femurs into 1 ml aliquots of RPMI medium using a 25-Raritan, NJ, USA) and Immunocount software (Ortho).
gauge needle: pooled cells were plated at a density of Nucleated cells were selected by forward and 90°light scat-1 × 10 4 cells per dish. ter and the fraction that was positive for HLA expression by immunofluorescence was measured. At least 5000 cells were analysed. Normal mouse PB was incubated with
Cell counting W632 antibody and used as a negative control; non-specific Cell counts were performed using a Coulter counter (model immunofluorescence from these populations was usually Z1; Coulter). For PB samples, normally 10 l heparinized 0.5-1% and was subtracted from other measurements. For blood was added to 10 ml Isoton (Coulter) for counting. single colony analysis, individual colonies of cells were Viability of human leukaemia cells was assessed before picked from agar cultures using a fine pipette tip and disimplantation using trypan blue dye (Sigma) exclusion. persed in 25 l PBR containing antibody. Murine colonies were identified using a phycoerythrin-conjugated monoclonal antibody specific for mouse CD45 (clone 30F11.1;
Measurements of levels of clonogenic HL60 leukaemia Pharmingen, San Diego, CA, USA). Samples were kept on cells ice for 30 min then diluted with 0.4 ml PBR for flow cytometry analysis. One hundred to 800 cells per colony were A model was devised for the study of HL60 cell migration into the PB. In addition to the ability to proliferate in SCID analysed (mean: 413).
mice, the HL60 cell line possesses a high growth factormice were monitored each week for the appearance of human cells in the PB. CML-1 xenografts were established independent cloning efficiency in semi-solid growth medium. Clonogenic HL60 cells can therefore be detected in six SCID mice. Treatment with G-CSF was started in three mice on day 21 after implantation and continued until at low frequency within cell suspensions derived from murine tissues, including those containing murine progeniday 24; three control mice were treated with PBS vehicle alone. AML-1 cells were implanted into eight recipients. tor cells with colony-forming ability. Clonogenic HL60 cells were assayed using the agar culture method described Treatment with G-CSF or PBS was started on individual mice after two consecutive measurements had shown that above, except that no CSF was added to cultures. Experiments were first performed to study the relative rates of the proportion of HLA-positive nucleated PB cells were at least twice that of negative controls (1-6% above control HL60 cell infiltration into BM, spleen and PB. Tissues were taken from groups of three mice at 8 later, using an automated system (Inotech Biosystems International, Jaffrey, NH, USA), cells were harvested on to cells; G-CSF treatment was started 12 days later and continued for 5 days. PB samples (100 l) were taken on days glass fibre filters and incorporated radioactivity counted directly. 4, 7 and 11 after the start of G-CSF treatment. MNCs were separated from 80 l of each sample and plated in equal numbers in two soft agar cultures, one containing murine CSF and one containing no exogenous growth factors. Total Results white blood cell (WBC) counts were also performed. Colony growth was analysed after 14 days. In a further experi-G-CSF mobilization of normal haemopoietic cell populations ment the rate at which HL60 cells migrated into the PB was directly compared in two groups of four leukaemiaIn normal SCID mice administration of G-CSF stimulated bearing mice treated with either G-CSF or PBS vehicle independent increases in the number of both total nucleated alone. Treatment was started 11 days after implantation of blood cells and HPCs in the PB (Figure 1 ). After 1 day of leukaemia cells. Clonogenic HL60 cells were detected by plating MNCs obtained from 40 l PB samples into non-CSF-supplemented agar cultures.
G-CSF stimulation of HL60 cells in vitro
HL60 cells from logarithmic growth phase stock cultures were re-seeded in 5 ml liquid cultures at 2 × 10 4 cells per ml. Triplicate cultures were supplemented with either 100 ng per ml G-CSF or PBS diluent alone. Cell counts were performed after 7 days.
Measurements of levels of CML-1 and AML-1 leukaemia cells
CML-1 cells showed only very limited proliferation in liquid suspension culture, and colony formation in semi- Numbers of HPCs in PB, capable of being stimulated to therefore, HL60 leukaemia cells were detected by clonogenic assay. These experiments also demonstrated that form colonies in vitro by IL-3 plus GM-CSF, were observed to be low in non-cytokine-stimulated SCID mice;
there was a period of at least 12 days during which transplanted HL60 cells proliferate in the BM before migrating the mean level not exceeding 29 per ml (Figure 1) . At 2 days following first G-CSF treatment the mean number (± in detectable numbers to the PB and spleen. Experiments were performed to investigate whether G-CSF-stimulated s.e.m.) of HPCs was 357 ± 14 per ml and at 5 days this was increased to 1171 ± 132 per ml PB (71 ± 6 per 1 × Figure 2 shows the increase in the number of clonogenic leukaemia cells folexpression. Cultures supplemented with murine CSF contained, in addition to leukaemic colonies, colonies with a lowing implantation. After 8 days low levels of infiltration were observed in BM, with no cells detected in the spleen morphology typical of normal PB progenitor cell colonies. These colonies contained a more diffuse distribution of cells and were often multi-focal. Cells derived from these ming cells grown in CSF-free culture, conditions which only support the development of human leukaemic colonies, also increased following the start of G-CSF treatment. However, the rate of increase was slower than that observed for normal PB progenitor cells, with maximum number observed at the termination of the experiment, 11 days after the start of treatment. The identification of colony origin on the basis of morphology was verified by flow cytometry analysis of cells from individual colonies grown from samples plated 11 days after the start of treatment in cultures containing murine CSF. Cells derived from colonies identified microscopically as murine did not express HLA (Figure 4 , left panels), whereas cells from colonies previously identified as leukaemic were shown to express HLA ( Figure 4 , right panels). Engraftment of BM with leukaemia was confirmed by flow cytometry in all mice at the end of the experiment. The mean fraction of HLA-positive BM cells was 7.8 ± 3.6% and the mean number of (CSFindependent) clonogenic cells was 147 ± 58 per 2 × 10 4 BM cells plated.
The effect of G-CSF on migration of leukaemic colonyforming cells to the PB was investigated in a further experiment (Figure 5a ). In both G-CSF-treated and control groups low numbers of circulating leukaemia cells were first detected 11 days after the start of treatment. These numbers were increased by day 15, when the experiment was terminated, with no significant difference observed between control and treated groups. Although numbers of clonogenic Figure 6a. The number of leukaemia cells in the PB remained unchanged for 2 days following the start of treatment. In normal SCID mice, as described above, ANC and colonies did not express HLA but were positive for murine CD45 expression (not shown).
the numbers of PB progenitor cells were increased within 2 days after the start of G-CSF treatment (Figure 1 ). Three ANC was increased approximately two-fold after 1 day of treatment. This was a smaller response than had been days following the start of treatment the numbers of CML-1 cells were increased. These changes were observed in observed in previous experiments using tumour-free, nonirradiated mice (Figure 1 ). Mean ANC before irradiation both G-CSF-treated mice and the control group, and are therefore interpreted as representing the natural progression was 10.7 ± 3.2 × 10 6 per ml PB, compared with 2.1 ± 0.3 × 10 6 per ml 12 days later (on the first day of Gof this leukaemia. The experiment was terminated after 4 days of cytokine treatment due to the advanced stage of CSF administration). Post-irradiation haemopoietic recovery was therefore incomplete at this time. No colonies grew the disease. from PB samples taken immediately before the first administration of G-CSF. Thereafter, numbers of colonies in
Effect of G-CSF on numbers of circulating AML-1 cells CSF-containing cultures which had diffuse-type morphology (murine) were observed to increase, reaching a Preliminary experiments had shown that, when compared with HL60 cells or CML-1 cells grown as xenografts, peak by day 7 and declining by day 11. The rate of increase in colony number was similar to that observed in non-leugrowth of passaged human AML-1 cells in SCID mice was relatively slow. In addition, and unlike CML-1 xenografts, kaemia-bearing mice (Figure 1 ). The number of colony-for- ment showed leukaemic infiltration of the BM in all mice (Figure 6b, histogram) . Human leukaemia cells represented between 55 and 96% of the total nucleated BM cells. Total the rise in AML-1 cell number in the PB following their first detection was also relatively slow and host survival BM cellularity was reduced by 70-92% compared with BM from untreated, non-engrafted SCID mice. was longer. Using this xenograft model it was therefore feasible to study the effects of G-CSF treatment when the number of leukaemia cells in the PB were low. Seven of G-CSF stimulation of leukaemia cell populations in vitro eight transplanted mice showed engraftment, with 0.2-4 × 10 5 leukaemia cells per ml PB on the first day of treatStimulation of HL60 cells by G-CSF in liquid culture produced a modest but significant (P Ͻ 0.001) increase in cell ment (45-56 days after AML cell inoculation). Three mice were administered G-CSF and four were treated with PBS number (Figure 5a, inset) . Proliferative responses to G-CSF by AML-1 and CML-1 cells, neither of which are capable vehicle alone.
Levels of leukaemia cells in the PB during cytokine of sustained growth ex vivo, were assessed using DNA incorporation of 3 H-thymidine. In cultures of AML-1 cells, administration are shown in Figure 6b . At 2-7 days following the start of treatment, when normal haemopoietic cell G-CSF concentrations of 1 ng per ml and above produced an approximate doubling of radioisotope labelling levels of mobilized HPCs this was shown to occur independently of cytokine treatment. In addition to inducing the ( Figure 7) . No proliferative response to G-CSF was observed in cultures of CML-1 cells (Figure 7) . relatively rapid mobilizations of normal nucleated blood cells and progenitor cells, G-CSF also stimulated a delayed increase in murine ANC which was probably due to a proliferative response of the BM. This was not accompanied Discussion by a rise in levels of clonogenic HL60 leukaemia cells in the PB. In mice transplanted with CML cells or AML cells, Treatment of SCID mice with G-CSF produced similar or more pronounced increases in total numbers of PB white the numbers of circulating leukaemia cells were also not increased by treatment with G-CSF. In at least two of the cells to those reported in normal mice. [21] [22] [23] The numbers of PB HPCs measured 7 days after first G-CSF treatment were leukaemias studied (HL60 and AML-1) this cannot be attributed to the absence of receptors for G-CSF, as both these increased 40-fold in SCID mice, and were comparable with PB levels of CFU-S and early haemopoietic progenitors in cell populations exhibited a proliferative response to G-CSF in vitro. These results may indicate that movements non-immune-deficient mice after G-CSF mobilization. 23, 24 Substantially greater increases in levels of circulating CFUof normal blood cells and leukaemia cells into the circulation are controlled by different mechanisms. It would be S have, however, also been reported. 21 In our experiments, the numbers of PB HPCs in SCID mice at day 7 represented of interest to compare directly G-CSF-stimulated mobilization of human leukaemia cells with mobilization of xenopeak levels, and this was consistent with the time at which PB cells with long-term in vivo repopulating capacity have grafted normal stem cells. However, our own experiments (unpublished observations) and those of others show susbeen detected following mobilization.
22,25 Stimulation with G-CSF also produced mobilization of normal WBCs and tained engraftment of only relatively low numbers of normal human multilineage progenitor cells in SCID mice, progenitor cells in HL60 leukaemia-bearing SCID mice, although with reduced efficacy. Total white cell count was except where repeated doses of human growth factors are administered.
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increased two-fold, compared to a five-fold increase in mice not implanted with HL60 cells. The peak levels of HPCs In this model of human leukaemia, the hypothesis that leukaemic cell contamination of PBSC harvests is enhanced in the PB were approximately 50% of those observed in non-engrafted mice. This was probably due to incomplete by G-CSF administration is not supported. Several studies, however, indicate the existence of multiple pathways of post-irradiation recovery of the BM in leukaemia-bearing mice. In mice treated with busulfan, a drug which has radio-PBSC mobilization. Recombinant rat SCF and recombinant human IL-11 have been shown to mobilize different submimetic effects on the BM, the numbers of subsequently mobilized progenitor cells have been shown to be populations of normal progenitor cells, 27 suggesting involvement of different mechanisms for mobilization. The decreased.
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In all three xenografted leukaemia cell lines that were very rapid mobilization of stem cells produced by BB-10010, a genetically engineered form of macrophage studied, progression of the disease in SCID mice was associated with the release of leukaemic cells into the PB. The inflammatory protein-1␣, 24 and by IL-8 28 also indicate an alternative mode of action. With the advent of novel cytocurrent experiments did not, however, show that this process was stimulated by treatment with G-CSF. Although kines into clinical mobilization protocols, the possibility that mechanisms for leukaemia cell mobilization into PB HL60 cells were detected in the PB concomitant with peak will be activated should not be discounted. haematological recovery times and supportive care require- 
